BUZZ-AstraZeneca: return-to-growth story - Bernstein

** Bernstein ups AstraZeneca (NYSE: AZN - news) to "outperform", citing big pipeline and potential take-out

** Broker sees co's LT EPS growth among the very best of the 9 major EI/US pharma cos it covers

** Bernstein considers co as a pipeline-driven, return-to-growth story, pointing that it has one of the fullest phase 3 pipelines

** "If industry consolidation occurs, between AZN's full pipeline, its superior growth and its comparatively smaller size, it could be a take-out candidate," Bernstein says

** Broker adds that there is no meaningful premium in share price at current level

** Bernstein's new TP, set at 5,780p, implies a 21 pct upside to the prevailing price level